Keytruda® (pembrolizumab) – New indication
June 13, 2018 - Merck announced the FDA approval of Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after ≥ 2 prior lines of therapy.
Download PDF
